Archive for January 2022

Intellia Therapeutics Inc. made history last summer when it became the first biotech company to successfully edit DNA inside the human body using CRISPR. Now, the company is planning to build on that momentum. Read More

Boston Mayor Michelle Wu’s "answer to everything is to tax developers — tax the rich — but this will just lead development to go elsewhere," writes Harry Johnston of Woburn. Read More

Following the spinout of its cancer business, bluebird bio Inc. is all in on gene therapy, with plans to launch three new drugs by the end of 2023. Read More

Ashkenazy has insisted that Clear Channel pay the usual $500,000 annual minimum, while Clear Channel says it owes much less because of the obstruction caused by the construction of the massive South Station air rights project. Read More

When Sanjay Dhawan resigned from the top role at Burlington-based Cerence Inc. last year, there was little explanation on the reasons behind his abrupt departure. His final destination is now public. Read More

The nation’s largest newspaper chain is discontinuing Saturday print editions starting March 5 at more than half of its newspapers nationwide. Read More

Iberdrola’s Avangrid Renewables unit has taken full ownership of Commonwealth Wind, the 1,200-megawatt project selected by the Baker administration in December to move forward. Read More

After a pandemic- and politics-fueled increase in online subscribers in 2020, the Boston Globe’s digital subscriptions leveled off, and even declined slightly last year for the first time, according to the newspaper’s filings. Read More

Israel’s Consul General to New England writes, "Let’s work together to ensure that persons with disabilities have access to life-changing technology, empowering them and ensuring their full accessibility." Read More